Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon
(PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease
progression of patients with metastatic Renal Cell Carcinoma. The first phase of this study
will determine the best dose of Peg-Intron, Sunitinib and Tarceva when given in combination.
The safety of giving these drugs in combination and response to treatment will also be
examined.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System